Empagliflozin reduces kidney fibrosis and improves kidney function by alternative macrophage activation in rats with 5/6-nephrectomy
Author:
Publisher
Elsevier BV
Subject
Pharmacology,General Medicine
Reference50 articles.
1. SGLT2 Inhibition for CKD and cardiovascular Ddisease in type 2 diabetes: report of a scientific workshop sponsored by the national kidney foundation;Tuttle;Diabetes,2021
2. Empagliflozin and progression of kidney disease in type 2 diabetes;Wanner;New Engl. J. Med.,2016
3. Canagliflozin and cardiovascular and renal events in type 2 diabetes;Neal;New Engl. J. Med.,2017
4. Dapagliflozin and cardiovascular outcomes in type 2 diabetes;Wiviott;New Engl. J. Med.,2019
5. Canagliflozin and renal outcomes in type 2 diabetes and nephropathy;Perkovic;New Engl. J. Med.,2019
Cited by 9 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献
1. SGLT2 inhibitor dapagliflozin protects the kidney in a murine model of Balkan nephropathy;American Journal of Physiology-Renal Physiology;2024-02-01
2. 2,8-Dihydroxyadenine-induced nephropathy causes hexosylceramide accumulation with increased mTOR signaling, reduced levels of protective SirT3 expression and impaired renal mitochondrial function;Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease;2024-01
3. The polarization of M2 macrophages can be adjusted to alleviate renal injury by methylprednisolone in sepsis-AKI;Archives of Biochemistry and Biophysics;2023-10
4. Artificially induced in situ macrophage polarization: An emerging cellular therapy for immuno-inflammatory diseases;European Journal of Pharmacology;2023-10
5. RNA-Seq transcriptomic landscape profiling of spontaneously hypertensive rats treated with a sodium-glucose cotransporter 2 (SGLT2) inhibitor;Biomedicine & Pharmacotherapy;2023-10
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3